Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Neurooncol. 2008 Sep;89(2):179-85. doi: 10.1007/s11060-008-9600-y. Epub 2008 Apr 23.

Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.

Author information

  • 1Department of Medical Oncology, Bellaria-Maggiore Hospital, Via Altura 3, 40139, Bologna, Italy.

Abstract

BACKGROUND:

Patients with recurrent or progressive low grade gliomas survive for a decade or more following diagnosis, and may be at a higher risk for treatment-related complications, such as cognitive impairment from radiotherapy.

PURPOSE:

The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status.

METHODS:

Progressive radio and chemotherapy naïve low grade glioma patients with O(6)-methyl-guanine-DNA-methyl-tranferase (MGMT) promoter status evaluation were considered eligible. Chemotherapy cycles consisted of temozolomide 75 mg/m(2)/daily for 21 days every 28 days for 12 cycles.

RESULTS:

A total of 30 patients (median age 45 [range: 24.2-68.6] years) with a median KPS of 90 (range 60-90) were accrued. The overall response rate was 30% (9 partial responses); 17 patients (56.7%) had disease stabilization.

CONCLUSION:

The prolonged temozolomide schedule considered in the present study is followed by a high response rate; toxicity is acceptable. Further randomized trials should therefore be conducted to confirm the efficacy of this regimen as first-line therapy in patients with progressive low grade glioma.

PMID:
18431544
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk